Drug Profile
Research programme: antibacterials - Array Biopharma/Replidyne
Alternative Names: DNA replication inhibitors - Array BioPharma/ReplidyneLatest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma; Replidyne
- Class Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 11 Sep 2008 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 12 Jun 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)